Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Puma Biotechnology stock in Canada | $10.55

Own Puma Biotechnology shares in just a few minutes.

Puma Biotechnology, Inc
NASDAQ: PBYI - USD
BIOTECHNOLOGY
$7.83
+$0.02 (+0.26%)

Puma Biotechnology is a biotechnology business based in the US. Puma Biotechnology stocks (PBYI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.08 – an increase of 6.78% over the previous week. Puma Biotechnology employs 267 staff and has a trailing 12-month revenue of around $272.1 million.

How to buy Puma Biotechnology stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PBYI in this case.
  5. Research Puma Biotechnology stocks. The platform should provide the latest information available.
  6. Buy your Puma Biotechnology stocks. It's that simple.

How has Coronavirus impacted Puma Biotechnology's stock price?

Since the stock market crash in March caused by coronavirus, Puma Biotechnology's stock price has had significant negative movement.

Its last market close was $10.55, which is 22.43% down on its pre-crash value of $13.6 and 91.82% up on the lowest point reached during the March crash when the stocks fell as low as $5.5.

If you had bought $1,000 worth of Puma Biotechnology stocks at the start of February 2020, those stocks would have been worth $917.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,312.21.

Puma Biotechnology stock price

Use our graph to track the performance of PBYI stocks over time.

Puma Biotechnology stocks at a glance

Information last updated 2021-07-23.
Latest market close$10.55
52-week range$7.48 - $14.14
50-day moving average $9.5471
200-day moving average $10.4112
Wall St. target price$9.57
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.41

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Puma Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Puma Biotechnology price performance over time

Historical closes compared with the last close of $10.55

1 month (2021-06-28) 16.19%
3 months (2021-04-28) 3.43%

Is Puma Biotechnology under- or over-valued?

Valuing Puma Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Puma Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Puma Biotechnology's PEG ratio

Puma Biotechnology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.03. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Puma Biotechnology's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Puma Biotechnology's EBITDA

Puma Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$35.1 million.

The EBITDA is a measure of a Puma Biotechnology's overall financial performance and is widely used to measure a its profitability.

Puma Biotechnology financials

Revenue TTM USD$272.1 million
Operating margin TTM 8.82%
Gross profit TTM USD$185.7 million
Return on assets TTM 6.2%
Return on equity TTM -205.58%
Profit margin -9.75%
Book value $0.408
Market capitalisation USD$332.6 million

TTM: trailing 12 months

How to short and sell Puma Biotechnology stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "PBYI.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 2.7 million Puma Biotechnology stocks held short by investors – that's known as Puma Biotechnology's "short interest". This figure is 28.4% down from 3.8 million last month.

There are a few different ways that this level of interest in shorting Puma Biotechnology stocks can be evaluated.

Puma Biotechnology's "short interest ratio" (SIR)

Puma Biotechnology's "short interest ratio" (SIR) is the quantity of Puma Biotechnology stocks currently shorted divided by the average quantity of Puma Biotechnology stocks traded daily (recently around 446941.12769486). Puma Biotechnology's SIR currently stands at 6.03. In other words for every 100,000 Puma Biotechnology stocks traded daily on the market, roughly 6030 stocks are currently held short.

However Puma Biotechnology's short interest can also be evaluated against the total number of Puma Biotechnology stocks, or, against the total number of tradable Puma Biotechnology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Puma Biotechnology's short interest could be expressed as 0.07% of the outstanding stocks (for every 100,000 Puma Biotechnology stocks in existence, roughly 70 stocks are currently held short) or 0.0908% of the tradable stocks (for every 100,000 tradable Puma Biotechnology stocks, roughly 91 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Puma Biotechnology.

Find out more about how you can short Puma Biotechnology stock.

Puma Biotechnology stock dividends

We're not expecting Puma Biotechnology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Puma Biotechnology stock price volatility

Over the last 12 months, Puma Biotechnology's stocks have ranged in value from as little as $7.48 up to $14.14. A popular way to gauge a stock's volatility is its "beta".

PBYI.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Puma Biotechnology's is 1.2448. This would suggest that Puma Biotechnology's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Puma Biotechnology overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Stocks similar to Puma Biotechnology

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site